Skip to content

MARLON

Active
Private limited companyfounded 199036 years activeMeersstraat 25, 1742 Ternat, BelgiumKBO/BCE: BE 0441.778.085
Summary

The computed 12-month bankruptcy probability of MARLON is 2.7% (moderate). The 2024 annual accounts show equity of €62,442 and a net result of -€50,166. Equity is growing by ~30.3% per year across the filed fiscal years. Its solvency ranks better than 42% of 86 sector peers (NACE 21, fiscal year 2024). The company has been active since 1990 and the Belgian State Gazette contains no insolvency or warning signals.

Overview

Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21100Limited-service restaurants, excluding mobile food services NACE 56112
#1 oldest company in Flemish Brabant, Pharmaceuticals sector2 sites
Size
€194,461total assets 2024
Staff
1.2 FTE
Equity
€62,442
Loss
-€50,166
Turnover not published (abridged schema)
Financial health
51 Fair Checked score 2024
Bankruptcy probabilitywithin 12 months
2.7%
Structure
Accounts 69 days overdue1 of 10 deeds read
Why 51- Loss of €50,166 (FY 2024)- Figures for FY 2024 (filed 01-10-2025)- 1 financial year not filed after the legal deadline; latest accounts 60 days late; 3 of the last 3 late+ Founded in 1990Show the evidence

Checked score

Score 2024
51 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 30% of its sector peers (NACE 21, micro)
Financial strength · tick = 2023
Weak
Solvency 57-11
equity 32.1% of total assets
Liquidity 43-45
short-term debt 26.7% · cash 3.0%
Profitability 0-75
return on assets -25.8%
Bankruptcy probability, 12 months
2.7% Moderate
0%0.5%1.5%4%10%≥ 25%

About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.3% (154 companies)
Last 24 months 11-2024: 0.5% 12-2024: 0.5%● unchanged vs 11-2024 01-2025: 0.5%● unchanged vs 12-2024 02-2025: 0.5%● unchanged vs 01-2025 03-2025: 0.5%● unchanged vs 02-2025lowest value 04-2025: 0.5%● unchanged vs 03-2025 05-2025: 0.5%● unchanged vs 04-2025 06-2025: 0.6%▲ +0.1 percentage points vs 05-2025 07-2025: 0.6%● unchanged vs 06-2025 08-2025: 0.9%▲ +0.3 percentage points vs 07-2025 09-2025: 1.1%▲ +0.2 percentage points vs 08-2025 10-2025: 1.7%▲ +0.6 percentage points vs 09-2025 11-2025: 3.1%▲ +1.4 percentage points vs 10-2025 12-2025: 3.1%● unchanged vs 11-2025 01-2026: 3.1%● unchanged vs 12-2025 02-2026: 3.1%● unchanged vs 01-2026 03-2026: 3.1%● unchanged vs 02-2026 04-2026: 3.1%● unchanged vs 03-2026 05-2026: 2.9%▼ -0.2 percentage points vs 04-2026 06-2026: 3.2%▲ +0.3 percentage points vs 05-2026highest value 07-2026: 1.7%▼ -1.5 percentage points vs 06-2026 08-2026: 2.2%▲ +0.5 percentage points vs 07-2026 09-2026: 2.3%▲ +0.1 percentage points vs 08-2026 10-2026: 2.7%▲ +0.4 percentage points vs 09-2026
Credit up to €3,000 at 30 days acceptable
Liquidity short (current ratio 0.21 against 1.9 in 2023; short-term debt: 26.7% and cash: 3% of total assets), and 67.9% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro): better than 47% on solvency, 44% on liquidity, 13% on profitability and 18% on growth.

The bankruptcy probability was computed on 07-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals.
−lowers risk+raises risk○neutral
lowers risk · Founded in 1990
How long the company has existed counts in the probability; how much depends on the rest of its profile.
KBO
raises risk · Loss of €50,166 (FY 2024)
NBB · annual accounts
raises risk · Figures for FY 2024 (filed 01-10-2025)
NBB · annual accounts
raises risk · 1 financial year not filed after the legal deadline; latest accounts 60 days late; 3 of the last 3 late
NBB · filings
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 29-09-2025, 60 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filings
Deviation from the deadline
2025
not confirmed
2024
60 days late
2023
78 days late
2022
112 days late
2021
77 days late
2020
81 days late
2019
70 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 6 accounts on average 80 days after the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (1)
neutral · No strike-offs in the KBO publications
Checked from 2021 on.
KBO publications · our coverage
  1. Resignation: DEVOS Dunja (director)Shareholding
  2. Annual accounts filedfiscal year 2024 · micro…
  3. Weakest financial yearnet -€50,166

Key points

  • Caution: From profit to loss in 2024after €13,123 in 2023 -€50,166 View
  • Positive: Oldest company in Flemish Brabant, Pharmaceuticals sectorin the Checked rankings #1 View
  • Caution: Accounts not fileddeadline was 31-07-2026 69 days late View
  • A director leftlatest change 06-03-2026 · 0 in office 1 left View

By topic

Financials

Fiscal year
2024
Total assets
€194,461
Loss
-€50,166
Solvency
32.1%
Total assets▼ 26.4%
Net result
20182024
Go to Financials

Timeline

Events
13
Since
2016
  1. 17-10-2024Annual accounts filed
  2. 31-12-2023Equity above €100,000
  3. 20-11-2023Annual accounts filed
Go to Timeline

Company details

Sites
2
Legal form
Private limited company
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21100
Founded
24-08-1990
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.